Puma Biotechnology is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. Co. in-licenses from Pfizer, Inc., the global development and commercialization rights to PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Co. is primarily focused on the development and commercialization of the oral version of neratinib, and its drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. We show 49 historical shares outstanding datapoints in our PBYI shares outstanding history coverage, used to compute PBYI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PBYI market cap history over the course of time is important for investors
interested in comparing PBYI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PBYI versus a peer is one thing; comparing
PBYI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PBYI can fluctuate over the course of history.
With this page we aim to empower investors researching PBYI by allowing them to research the PBYI market cap history. |
Free PBYI Email Alerts:
Video: The Importance of Market Cap
